Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, announced it will release its Q3 2024 financial results on Wednesday, November 6, 2024, before market open. The company will host a live webcast at 8am ET on the same day. Investors can access the webcast through a registration link or the company's website. A replay will be available for 90 days on the company's website.
Praxis Precision Medicines (NASDAQ: PRAX), un'azienda biopharmaceutical in fase clinica focalizzata sullo sviluppo di terapie per i disturbi del SNC, ha annunciato che rilascerà i suoi risultati finanziari del Q3 2024 mercoledì 6 novembre 2024, prima dell'apertura del mercato. L'azienda ospiterà un webcast dal vivo alle 8:00 ET nello stesso giorno. Gli investitori possono accedere al webcast tramite un link di registrazione o il sito web dell'azienda. Una registrazione sarà disponibile per 90 giorni sul sito web dell'azienda.
Praxis Precision Medicines (NASDAQ: PRAX), una empresa biofarmacéutica en fase clínica centrada en el desarrollo de terapias para trastornos del sistema nervioso central, anunció que publicará sus resultados financieros del Q3 2024 el miércoles 6 de noviembre de 2024, antes de la apertura del mercado. La empresa realizará una transmisión en vivo a las 8:00 AM ET ese mismo día. Los inversores pueden acceder a la transmisión a través de un enlace de registro o del sitio web de la empresa. Se ofrecerá una repetición durante 90 días en el sitio web de la empresa.
Praxis Precision Medicines (NASDAQ: PRAX), 임상 단계의 생명공학 회사로 CNS 장애 치료제 개발에 집중하고 있으며, 2024년 11월 6일 수요일에 2024년 3분기 재무 결과를 시장 개장 전에 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시에 ET 기준으로 라이브 웹캐스트를 진행할 예정입니다. 투자자들은 등록 링크나 회사 웹사이트를 통해 웹캐스트에 접속할 수 있습니다. 재방송은 회사 웹사이트에서 90일 동안 제공될 예정입니다.
Praxis Precision Medicines (NASDAQ: PRAX), une entreprise biopharmaceutique à un stade clinique axée sur le développement de thérapies pour les troubles du SNC, a annoncé qu'elle publiera ses résultats financiers du T3 2024 le mercredi 6 novembre 2024, avant l'ouverture des marchés. L'entreprise organisera un webinaire en direct à 8h00 ET ce même jour. Les investisseurs peuvent accéder au webinaire via un lien d'inscription ou le site web de l'entreprise. Un replay sera disponible pendant 90 jours sur le site web de l'entreprise.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von Therapien für CNS-Erkrankungen konzentriert, gab bekannt, dass es am Mittwoch, den 6. November 2024, vor Markteröffnung seine Finanzergebnisse für Q3 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 8 Uhr ET eine Live-Webcast veranstalten. Investoren können über einen Registrierungslink oder die Unternehmenswebsite auf den Webcast zugreifen. Eine Wiederholung wird 90 Tage lang auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024.
The Company will host a live webcast the same morning at 8am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
When will Praxis Precision Medicines (PRAX) release Q3 2024 earnings?
What time is Praxis Precision Medicines (PRAX) Q3 2024 earnings call?
How long will Praxis Precision Medicines (PRAX) Q3 2024 earnings call replay be available?
